0001933414-23-000090.txt : 20231113 0001933414-23-000090.hdr.sgml : 20231113 20231113082021 ACCESSION NUMBER: 0001933414-23-000090 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231111 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231113 DATE AS OF CHANGE: 20231113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mineralys Therapeutics, Inc. CENTRAL INDEX KEY: 0001933414 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41614 FILM NUMBER: 231395342 BUSINESS ADDRESS: STREET 1: 150 N. RADNOR CHESTER ROAD STREET 2: SUITE F200 CITY: RADNOR STATE: PA ZIP: 19087 BUSINESS PHONE: (888) 378-6240 MAIL ADDRESS: STREET 1: 150 N. RADNOR CHESTER ROAD STREET 2: SUITE F200 CITY: RADNOR STATE: PA ZIP: 19087 8-K 1 mlys-20231111.htm 8-K mlys-20231111
false000193341400019334142023-11-112023-11-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 11, 2023
MINERALYS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-41614
84-1966887
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
150 N. Radnor Chester Road, Suite F200
Radnor, Pennsylvania 19087
(Address of principal executive offices) (Zip Code)
(888) 378-6240
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
MLYS
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 7.01. Regulation FD Disclosure.
On November 11, 2023, Mineralys Therapeutics, Inc. (the “Company”) issued a press release announcing its presentation of data from the Target-HTN Phase 2 trial that further defines an endotype-specific targeted approach for treating uncontrolled or resistant hypertension with lorundrostat. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.
Item 8.01. Other Events.
On November 11, 2023, the Company presented data from the Target-HTN Phase 2 trial that further defines an endotype-specific targeted approach for treating uncontrolled or resistant hypertension with lorundrostat, a highly selective aldosterone synthase inhibitor. The data were presented in a poster at the American Heart Association (AHA) Scientific Sessions 2023, which is being held in Philadelphia from November 11th – 13th.
Data previously presented from Target-HTN showed that elevated body mass index (BMI) was predictive of an enhanced reduction in systolic blood pressure (BP) from lorundrostat treatment. The poster presented at the AHA Scientific Sessions 2023 included a new analysis of serum leptin levels among subjects in the trial, which showed that increased BMI was correlated with increased leptin circulation. This is consistent with emerging evidence of a leptin-driven, positive feedback loop between obesity, aldosterone and hypertension.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
Press Release Issued on November 11, 2023
104Cover Page Interactive Date File (embedded within the Inline XBRL document)
Forward-Looking Statements
Mineralys Therapeutics cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the Company’s expectation that aldosterone synthase inhibitors with an SGLT2 inhibitor may provide additive clinical benefits to patients; the Company’s expectation that the Advance-HTN and the planned Phase 3 clinical trial of lorundrostat may serve as pivotal trials in any submission of a new drug application (NDA) to the United States Food and Drug Administration (FDA); the Company’s ability to evaluate lorundrostat as a potential treatment for chronic kidney disease or uncontrolled hypertension; the planned future clinical development of lorundrostat and the timing thereof; and the expected timing of commencement and enrollment of patients in clinical trials and topline results from clinical trials. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in our business, including, without limitation: our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; later developments with the FDA may be inconsistent with the feedback from the completed end of Phase 2 meeting, including whether the proposed pivotal program will support registration of lorundrostat which is a review issue with the FDA upon submission of an NDA; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; our ability to maintain undisrupted business operations


due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; our reliance on our exclusive license with Mitsubishi Tanabe Pharma to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 13, 2023MINERALYS THERAPEUTICS, INC.
By:/s/ Adam Levy
Name:Adam Levy
Title:Chief Financial Officer, Chief Business Officer and Secretary

 EX-99.1 2 mlys202311118kex991.htm EX-99.1 Document
Exhibit 99.1
image_0.jpg
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023
– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone –
– Excess aldosterone in patients with visceral obesity defines a unique hypertensive endotype with potential for an enhanced response to aldosterone-targeted therapy with lorundrostat –
– Early identification and intervention with lorundrostat may result in improved clinical outcomes for obese patients with uncontrolled or resistant hypertension –
RADNOR, PA – November 11, 2023 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today presented data from the Target-HTN Phase 2 trial that further defines an endotype-specific targeted approach for treating uncontrolled or resistant hypertension with lorundrostat, a highly selective aldosterone synthase inhibitor. The data were presented in a poster at the American Heart Association (AHA) Scientific Sessions 2023, which is being held in Philadelphia from November 11th –13th.
Data previously presented from Target-HTN showed that elevated body mass index (BMI) was predictive of an enhanced reduction in systolic blood pressure (BP) from lorundrostat treatment. The poster presented at the AHA Scientific Sessions 2023 included a new analysis of serum leptin levels among subjects in the trial, which showed that increased BMI was correlated with increased leptin circulation. This is consistent with emerging evidence of a leptin-driven, positive feedback loop between obesity, aldosterone and hypertension.1
“Through our ongoing analyses of data from the Target-HTN trial, a profile of which patients can benefit the most from lorundrostat is emerging. After examining serum leptin levels across participants, we now have evidence that this hormone, along with elevated BMI, could be a biomarker for patients who may experience a meaningful blood pressure reduction from lorundrostat treatment,” stated David Rodman, M.D., Chief Medical Officer for Mineralys. “Obesity is an epidemic and is one of the strongest risk factors for developing hypertension, which results in subsequent poor outcomes if uncontrolled. Being able to identify a hypertensive endotype, and intervene early with aldosterone-targeted therapy, would change the way clinicians currently treat the condition in practice by introducing a precision approach to care.”
A pre-specified analysis from Target-HTN showed that subjects with a BMI >30kg/m2 experienced placebo-adjusted reductions in systolic BP of 16.7mmHg (p=0.002) and 12.3mmHg (p=0.03) with lorundrostat 50mg and 100mg once-daily (QD) doses, respectively. Findings from the new analysis showed that the same BMI range was associated with a 75% increase in mean serum leptin (21.6 ±1.9ng/mL in subjects with a BMI ≤30kg/m2 compared to 37.8 ±2.4ng/mL in subjects with a BMI >30kg/m2; p<0.001), indicating that increased circulating leptin may be a useful biomarker to identify lorundrostat-responsive individuals.
The Target-HTN trial demonstrated that treatment with lorundrostat at doses of 50mg and 100mg QD led to a statistically and clinically significant reduction of systolic BP in uncontrolled hypertensive individuals on at least two background antihypertensive medications. Full results from the trial were published in the Journal of the American Medical Association (JAMA) and simultaneously presented


during a late-breaking science session at the 2023 AHA Hypertension Scientific Sessions in September.
Target-HTN trial results support the transition to late-stage development of lorundrostat as a treatment for uncontrolled or resistant hypertension. The Company’s ongoing pivotal development program for lorundrostat to treat uncontrolled or resistant hypertension is currently enrolling subjects in the pivotal Advance-HTN trial, and the second pivotal trial, Launch-HTN, trial is expected to be initiated in the second half of 2023.
The poster at AHA Scientific Sessions 2023 titled, “Lorundrostat for Treatment of Obesity-Related, Aldosterone-Dependent Hypertension - An Endotype-Specific, Targeted Approach to the Treatment of Uncontrolled Hypertension,” can be accessed on the publications page of the Mineralys corporate website.
About Target-HTN
The Target-HTN (NCT05001945) Phase 2 proof-of-concept trial was a randomized, double-blind, placebo-controlled, dose-ranging, multicenter trial conducted in the U.S. The trial was designed to evaluate the safety, efficacy, tolerability and dose response of orally administered lorundrostat on BP for the treatment of uncontrolled or resistant hypertension when used as add-on therapy to stable background treatment of two or more antihypertensive agents in 200 male and female subjects 18 years of age or older. Five active doses of lorundrostat (12.5mg QD, 50mg QD, 100mg QD, 12.5mg twice daily (BID), and 25mg BID) were compared to placebo in hypertensive subjects. Adverse events observed were a modest increase in serum potassium, decrease in estimated glomerular filtration rate, urinary tract infection and hypertension with one serious adverse event possibly related to study drug being hyponatremia.
About Hypertension
Having sustained, elevated blood pressure (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the U.S. In 2020, more than 670,000 deaths in the U.S. included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an average annual economic burden of about $130 billion each year in the U.S., averaged over 12 years from 2003 to 2014.
Less than 50 percent of hypertension patients achieve their blood pressure goal with currently available medications. Abnormally elevated aldosterone levels are a key factor in driving hypertension in approximately 25 percent of all hypertensive patients.
About Lorundrostat
Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension and CKD. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated approximately a 70% reduction in plasma aldosterone concentration in hypertensive subjects.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions


affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Forward-Looking Statements
Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the Company’s expectation that aldosterone synthase inhibitors with an SGLT2 inhibitor may provide additive clinical benefits to patients; the Company’s expectation that the Advance-HTN and the planned Phase 3 clinical trial of lorundrostat may serve as pivotal trials in any submission of a new drug application (NDA) to the United States Food and Drug Administration (FDA); the Company’s ability to evaluate lorundrostat as a potential treatment for CKD or uncontrolled hypertension; the planned future clinical development of lorundrostat and the timing thereof; and the expected timing of commencement and enrollment of patients in clinical trials and topline results from clinical trials. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; later developments with the FDA may be inconsistent with the feedback from the completed end of Phase 2 meeting, including whether the proposed pivotal program will support registration of lorundrostat which is a review issue with the FDA upon submission of an NDA; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; our ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; our reliance on our exclusive license with Mitsubishi Tanabe Pharma to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
References:
1 Faulkner JL, et al. Curr Opin Nephrol Hypertens. 2081;27(2):63-69.


Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com

 EX-101.SCH 3 mlys-20231111.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mlys-20231111_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 5 mlys-20231111_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image_0.jpg begin 644 image_0.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 11, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 11, 2023
Entity Registrant Name MINERALYS THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-41614
Entity Tax Identification Number 84-1966887
Entity Address, Address Line One 150 N. Radnor Chester Road
Entity Address, Address Line Two Suite F200
Entity Address, City or Town Radnor
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19087
City Area Code 888
Local Phone Number 378-6240
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol MLYS
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Amendment Flag false
Entity Central Index Key 0001933414
XML 8 mlys-20231111_htm.xml IDEA: XBRL DOCUMENT 0001933414 2023-11-11 2023-11-11 false 0001933414 8-K 2023-11-11 MINERALYS THERAPEUTICS, INC. DE 001-41614 84-1966887 150 N. Radnor Chester Road Suite F200 Radnor PA 19087 888 378-6240 false false false false Common Stock, par value $0.0001 per share MLYS NASDAQ true false 2023-11-11 2023-11-11 EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6 M,P$ "(" / " 800 !X;"]W;W)K8F]O:RYX;6Q02P$" M% ,4 " "*0FU7)!Z;HJT #X 0 &@ @ 'D$0 >&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "*0FU799!YDAD! M #/ P $P @ ')$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+ 4!08 "0 ) #X" 3% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.mineralystx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports mlys-20231111.htm mlys-20231111.xsd mlys-20231111_lab.xml mlys-20231111_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mlys-20231111.htm": { "nsprefix": "mlys", "nsuri": "http://www.mineralystx.com/20231111", "dts": { "inline": { "local": [ "mlys-20231111.htm" ] }, "schema": { "local": [ "mlys-20231111.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "mlys-20231111_lab.xml" ] }, "presentationLink": { "local": [ "mlys-20231111_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://www.mineralystx.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mlys-20231111.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mlys-20231111.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.mineralystx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001933414-23-000090-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001933414-23-000090-xbrl.zip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end